Salivary and serum level of CYFRA 21-1 in oral precancer and oral squamous cell carcinoma

Oral Diseases

Volumn 21, Issue 1, 2015, Pages 90-96

  Rajkumar, K ^a   Ramya, R ^a   Nandhini, G ^a   Rajashree, P ^a   Ramesh Kumar, A ^a   Nirmala Anandan, S ^a  

^a SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

CYFRA 21 1; Diagnosis; Oral cancer; Premalignant lesion; Squamous cell carcinoma

Indexed keywords

CYTOKERATIN 19 FRAGMENT; ANTIGEN CYFRA21.1; CYTOKERATIN 19; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PRECANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SALIVA ANALYSIS; SALIVA LEVEL; BLOOD; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; CHEMISTRY; MIDDLE AGED; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; SALIVA; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KERATIN-19; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; SALIVA; YOUNG ADULT;

EID: 84919413387     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12216     Document Type: Article

References (33)

1. Ausch C, Buxhofer-Ausch V, Olszewski U, Hamilton G (2010). Circulating cytokeratin 18 fragments and activation of dormant tumor cells in bone marrow of cancer patients. Exp Ther Med 1: 9-12.
2. Bonfrer JM, Gaarenstroom KN, Korse CM, Van Bunningen BN, Kenemans P (1997). Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Anticancer Res 17: 2329-2334.
3. Brockmann JG, St Nottberg H, Glodny B, Heinecke A, Senninger NJ (2000). CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 6: 4249-4252.
4. Broers JL, Carney DN, de Ley L, Vooijs GP, Ramaekers FC (1985). Differential expression of intermediate filament proteins distinguishes classic from variant small-cell lung cancer cell lines. Proc Natl Acad Sci USA 82: 4409-4413.
5. Broers JL, Ramaekers FC, Rot MK et al (1988). Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res 48: 3221-3229.
6. Cheng B, Rhodus NL, Williams B, Griffin RJ (2004). Detection of apoptotic cells in whole saliva of patients with oral premalignant and malignant lesions: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97: 465-470.
7. Doweck I, Barak M, Greenberg E et al (1995). Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 121: 177-181.
8. Feng XY, Li JH, Li JZ, Han ZX, Xing RD (2010). Serum SCCA, Cyfra 21-1, EGFR and Cyclin D1 levels in patients with oral squamous cell carcinoma. Int J Biol Markers 25: 93-98.
9. Gasparoni A, Squier CA, Fonzi L (2005). Cytokeratin changes in cell culture systems of epithelial cells isolated from oral mucosa: a short review. Ital J Anat Embryol 110: 75-82.
10. Gomez I, Warnakulasuriya S, Varela-Centelles PI et al (2010). Is early diagnosis of oral cancer a feasible objective? Who is to blame for diagnostic delay? Oral Dis 16: 333-342.
11. Gupta PC, Bhonsle RB, Murti PR, Daftary DK, Mehta FS, Pindborg JJ (1989). An epidemiologic assessment of cancer risk in oral precancerous lesions in India with special reference to nodular leukoplakia. Cancer 63: 2247-2252.
12. Hamakawa H, Bao Y, Takarada M, Fukuzumi M, Tanioka H (1998). Cytokeratin expression in squamous cell carcinoma of the lung and oral cavity: an immunohistochemical study with possible clinical relevance. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85: 438-443.
13. Kao CH, Hsieh JF, Ho YJ, Tsai SC, Lee JK (1999). Cytokeratin fragment 19 (CYFRA 21-1) in healthy smokers. Anticancer Res 19: 4545-4546.
14. Kawaguchi H, Ohno S, Miyazaki M et al (2000). CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer 89: 1413-1417.
15. Kurokawa H, Yamashita Y, Tokudome S, Kajiyama M (1997). Combination assay for tumor markers in oral squamous cell carcinoma. J Oral Maxillofac Surg 55: 964-966.
16. Lalli A, Tilakaratne WM, Ariyawardana A et al (2008). An altered keratinocyte phenotype in oral submucous fibrosis: correlation of keratin K17 expression with disease severity. J Oral Pathol Med 37: 211-220.
17. Liu J, Duan Y (2012). Saliva: a potential media for disease diagnostics and monitoring. Oral Oncol 48: 569-577.
18. Liu W, Wang YF, Zhou HW, Shi P, Zhou ZT, Tang GY (2010). Malignant transformation of oral leukoplakia: a retrospective cohort study of 218 Chinese patients. BMC Cancer 10: 685.
19. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R (1982). The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31: 11-24.
20. Nagler RM (2009). Saliva as a tool for oral cancer diagnosis and prognosis. Oral Oncol 45: 1006-1010.
21. Nagler R, Bahar G, Shpitzer T, Feinmesser R (2006). Concomitant analysis of salivary tumor markers-a new diagnostic tool for oral cancer. Clin Cancer Res 12: 3979-3984.
22. Nakata B, Chung YS, Kato Y et al (1996). Clinical significance of serum CYFRA 21-1 in gastric cancer. Br J Cancer 73: 1529-1532.
23. Nisman B, Lafair J, Heching N et al (1998). Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer 82: 1850-1859.
24. Petersen PE (2009). Global policy for improvement of oral health in the 21st century-implications to oral health research of World Health Assembly 2007, World Health Organization. Commun Dent Oral Epidemiol 37: 1-8.
25. Shiu MN, Chen TH (2003). Intervention efficacy and malignant transformation to oral cancer among patients with leukoplakia (Review). Oncol Rep 10: 1683-1692.
26. Sugama Y, Kitamura S, Kawai T et al (1994). Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res 85: 1178-1184.
27. Warnakulasuriya S (2009). Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45: 309-316.
28. Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T (1997). CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 79: 1647-1655.
29. Yan HJ, Wang RB, Zhu KL et al (2012). Cytokeratin 19 fragment antigen 21-1 as an independent predictor for definitive chemoradiotherapy sensitivity in esophageal squamous cell carcinoma. Chin Med J (Engl) 125: 1410-1415.
30. Yen TC, Lin WY, Kao CH, Cheng KY, Wang SJ (1998). A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol Allied Sci 23: 82-86.
31. Yi Y, Li B, Wang Z, Sun H, Gong H, Zhang Z (2009). CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Biomarkers 14: 480-485.
32. Zhong LP, Zhang CP, Zheng JW, Li J, Chen WT, Zhang ZY (2007a). Increased Cyfra 21-1 concentration in saliva from primary oral squamous cell carcinoma patients. Arch Oral Biol 52: 1079-1087.
33. Zhong LP, Zhu HG, Zhang CP, Chen WT, Zhang ZY (2007b). Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma. Int J Oral Maxillofac Surg 36: 230-234.